New antibody drug takes aim at Hard-to-Treat cancers
NCT ID NCT06126666
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a new drug called ABL103 in people with advanced solid tumors that have not responded to standard treatments. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The study will enroll 96 participants to evaluate safety, dosing, and any signs of tumor shrinkage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ABL103 (a bispecific antibody that targets two proteins on cancer cells to boost immune response)
What this could lead to
If successful, this could lead to a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 96 participants, so it is primarily testing safety and dosing. The drug may not shrink tumors or may cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Seoul National University Bundang Hospital
RECRUITINGSeongnam, Seoul, 13620, South Korea
Contact
Contact Email: •••••@•••••
-
Seoul National University Hospital
NOT_YET_RECRUITINGSeoul, Seoul, 03080, South Korea
Contact Email: •••••@•••••
-
Sevrance Hospital
RECRUITINGSeoul, South Korea, 03722, South Korea
Contact Email: •••••@•••••